BioHarvest Sciences (NASDAQ:BHST) Posts Quarterly Earnings Results, Misses Estimates By $0.05 EPS

BioHarvest Sciences (NASDAQ:BHST) released its earnings results on Monday. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.05), Zacks reports. The business had revenue of $7.17 million for the quarter, compared to analysts’ expectations of $7.24 million.

BioHarvest Sciences Stock Up 4.8 %

Shares of NASDAQ BHST traded up $0.30 during mid-day trading on Tuesday, hitting $6.49. 5,224 shares of the company traded hands, compared to its average volume of 8,004. BioHarvest Sciences has a 1 year low of $6.15 and a 1 year high of $7.38. The business’s 50 day moving average is $5.66. The firm has a market cap of $106.60 million, a PE ratio of -5.20 and a beta of 2.27.

Wall Street Analysts Forecast Growth

BHST has been the topic of several recent research reports. Maxim Group initiated coverage on BioHarvest Sciences in a report on Wednesday, December 18th. They issued a “buy” rating and a $12.00 price target on the stock. HC Wainwright began coverage on BioHarvest Sciences in a research note on Friday, December 6th. They set a “buy” rating and a $14.00 price target for the company.

BioHarvest Sciences Company Profile

BioHarvest Sciences Inc is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications.